Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of AbCellera Biologics Inc (NASDAQ: ABCL) closed at $2.02 in the last session, down -0.49% from day before closing price of $2.03. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 2.3 million shares were traded.
Ratios:
We take a closer look at ABCL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.15 and its Current Ratio is at 10.15. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 26.08 while its Price-to-Book (P/B) ratio in mrq is 0.59.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $4.34, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -12.10%, while the 200-Day Moving Average is calculated to be -24.83%.
Shares Statistics:
A total of 298.36M shares are outstanding, with a floating share count of 223.95M. Insiders hold about 24.97% of the company’s shares, while institutions hold 37.39% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.58 and -$0.76 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.63, with 5.0 analysts recommending between -$0.37 and -$0.81.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $7.55M. It ranges from a high estimate of $21.06M to a low estimate of $4.67M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $7.32MFor the next quarter, 9 analysts are estimating revenue of $7.57M. There is a high estimate of $20.66M for the next quarter, whereas the lowest estimate is $4.31M.
A total of 10 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $68.74M, while the lowest revenue estimate was $17.43M, resulting in an average revenue estimate of $26.92M. In the same quarter a year ago, actual revenue was $28.83MBased on 8 analysts’ estimates, the company’s revenue will be $52.58M in the next fiscal year. The high estimate is $175.91M and the low estimate is $22.9M.
